StockData
Accustem Sciences Inc. logo

Accustem Sciences Inc. (ACUT) stock

ACUTOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$0.15+0.00 (0.00%)

Close on Oct 16, 2026Market cap $2.37MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$2.37M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$1.65M
EPS, diluted
-$0.10
Book value per share
-$0.26
Diluted shares
16M

Trading

Previous close
$0.15
Open
$0.15
Day's range
$0.15 – $0.15
Volume
0
Average volume (20 days)
2,549

Market cap history

Month-end market cap since 2022, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodACUTS&P 500DifferenceACUT per yearS&P 500 per year
1 month+13.2%+1.5%+11.8 pts
3 months-28.1%+1.9%−30.0 pts
Year to date-81.9%+12.8%−94.7 pts
1 year-85.5%+16.8%−102.3 pts
3 years-79.0%+81.5%−160.5 pts-40.6%+22.0%

Six years at a glance

Fiscal years 2020 to 2025 and trailing twelve months, USD

Operating income

-$1.65M

Net income

-$1.65M

EPS, diluted

-$0.10

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Accustem Sciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update

About Accustem Sciences

Pharmaceutical Preparations

AccuStem Sciences, Inc. is a clinical-stage diagnostics company that develops and commercializes genomic tests to assist decision-making across oncology care. Its proprietary test pipeline includes the MicroRNA Signature Classifier, a 24-microRNA blood-based assay designed to determine whether lung nodules identified through low-dose computed tomography screening are benign or malignant. The company also develops StemPrintER, a 20-gene prognostic assay measuring tumor stemness to evaluate the risk of distant recurrence in patients diagnosed with early-stage, luminal breast cancer. Additionally, it plans to provide ancillary testing services such as hereditary genetic and somatic mutation panels.

Company profile, executives and history

Accustem Sciences stock: common questions

What is Accustem Sciences's stock price?

ACUT closed at $0.15 on Oct 16, 2026, up 0.00% on the day.

What is Accustem Sciences's market cap?

Accustem Sciences was worth $2.37M at the close on Oct 16, 2026: the share price times the diluted shares outstanding.

What is ACUT's P/E ratio?

Accustem Sciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.10), so it has no meaningful P/E ratio.

Does Accustem Sciences pay a dividend?

No. Accustem Sciences has not paid a cash dividend over the last twelve months.

How has ACUT stock performed over the past year?

Including dividends, ACUT returned -85.5% over the past year, against +16.8% for the S&P 500.

Who are Accustem Sciences's competitors?

Companies most similar to Accustem Sciences by business, industry and size include ALLR, ONCO, ACRV, ATNM, GNPX.

See a number that looks wrong?